Active Ingredient
(in each tablet)
Dimenhydrinate 50 mg
The following Structured Product Label (SPL) was submitted to the FDA by Medtech Products Inc. for the product Dramamine Orange (NDC 63029-902). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding active ingredient, purpose, use, do not giveto, ask a doctor before use if you have, ask a doctor or pharmacist before use, when using this product, if pregnant or breast-feeding,, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
(in each tablet)
Dimenhydrinate 50 mg
Antiemetic
for prevention and treatment of these symptoms associated with motion sickness
children under 2 years of age unless directed by a doctor
if you are taking sedatives or tranquilizers
ask a doctor before use.
In case of accidental overdose, get medical help or contact a Poison Control Center (1-800-222-1222) right away.
to prevent motion sickness, the first dose should be taken ½ to 1 hour before starting activity
to prevent or treat motion sickness, see below:
| Adults and children 12 years and over |
|
| Children 6 to under 12 years |
|
| Children 2 to under 6 years |
|
anhydrous citric acid, aspartame, FD&C yellow #6 aluminum lake, flavors, magnesium stearate, maltodextrin, methacrylic acid copolymer, modified starch, sorbitol
Call 1-800-382-7219
Dimenhydrinate Tablets/Antiemetic
CHEWABLE FORMULA
Dramamine
®
MOTION SICKNESS RELIEF
DUAL ACTION
1. TREATS SYMPTOMS ON THE SPOT
2. PREVENTS NAUSEA, DIZZINESS & VOMITING
Convenient Chewable Tablets
8 ORANGE FLAVORED TABLETS (50 mg EACH)
Dimenhydrinate Tablets/Antiemetic
CHEWABLE FORMULA
Dramamine
®
MOTION SICKNESS RELIEF
DUAL ACTION
1. TREATS SYMPTOMS ON THE SPOT
2. PREVENTS NAUSEA, DIZZINESS & VOMITING
Convenient Chewable Tablets
2 ORANGE FLAVORED TABLETS (50 mg EACH)
* Please review the disclaimer below.